Table 1.
Clinical characteristics of patients who underwent focal/partial or whole gland brachytherapy
| All patients (N= 60) | Focal/partial BT (n= 30) | Whole gland BT (n= 30) | P-value | ||
|---|---|---|---|---|---|
| Age (years) | 65.5 (60.0-75.8) | 68.0 (59.8-76.5) | 64.5 (59.8-75.3) | 0.285 | |
| Initial PSA (ng/ml) | 6.7 (5.1-10.5) | 7.6 (5.5-10.3) | 5.9 (4.7-10.9) | 0.002 | |
| Prostate volume (ml) | 28.2 (24.0-38.8) | 27.6 (23.2-31.2) | 32.6 (24.2-40.3) | 0.097 | |
| Clinical stage, n(%) | 0.001 | ||||
| cT1 | 9 (15.0) | 9 (30.0) | 0 (0) | ||
| cT2a | 24 (40.0) | 13 (43.3) | 11 (36.7) | ||
| cT2b | 9 (15.0) | 2 (6.7) | 7 (23.3) | ||
| cT2c | 15 (25.0) | 6 (20.0) | 9 (30.0) | ||
| cT3a | 3 (5.0) | 0 (0) | 3 (10.0) | ||
| Biopsy Gleason (ISUP), n(%) | 0.317 | ||||
| 6 (1) | 30 (50.0) | 17 (56.7) | 13 (43.3) | ||
| 7 (2 or 3) | 25 (41.7) | 11 (36.7) | 14 (46.7) | ||
| 8 (4) | 4 (6.7) | 2 (6.7) | 3 (10.0) | ||
| D’Amico risk group, n(%) | 0.098 | ||||
| Low-risk | 14 (23.3) | 10 (33.3) | 4 (13.3) | ||
| Intermediate-risk | 41 (68.3) | 18 (60.0) | 23 (76.7) | ||
| High-risk | 5 (8.3) | 2 (6.7) | 3 (10.0) | ||
| Number of seeds | 45.5 (40.0-59.5) | 40.0 (37.8-40.5) | 59.0 (53.8-65.0) | < 0.001 | |
| Follow-up duration, months | 45.0 (35.2-56.7) | 37.3 (27.8-43.2) | 54.9 (47.9-60.5) | < 0.001 | |
All values are given as medians (interquartile ranges) or numbers (%) of patients. BT – brachytherapy, ISUP – International Society of Urologic Pathology